Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate Cancer

This study has been completed.
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Information provided by:
Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00139191
First received: August 29, 2005
Last updated: October 30, 2009
Last verified: October 2009

August 29, 2005
October 30, 2009
July 2005
Not Provided
To explore the associations between measures of C-11 acetate uptake and retention into prostate tumors and levels of FAS expression in tissue.
Same as current
Complete list of historical versions of study NCT00139191 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate Cancer
A Pilot Study Evaluating the Correlation Between Carbon 11 Acetate (C-11 Acetate) Uptake and Retention as Measured by Positron Emission Tomography (PET) and Fatty Acid Synthase (FAS) Expression in Prostate Cancer

The purpose of this study is to understand if a new type of radiology test called positron emission tomography (PET) with carbon 11 acetate will help us to understand which cancers produce more of a protein called fatty acid synthase (FAS).

  • Within 4 weeks of the patient's scheduled surgery they will undergo a C11 acetate PET scan. This scan will be performed at the Massachusetts General Hospital's Nuclear Medicine Department and involves an intravenous injection of acetate with a radioactive tracer followed by a PET scan. The scan will determine how well the tumor is taking up the acetate.
  • Patients will also undergo a CT scan of the pelvis at the same time as the PET scan.
  • After surgery, the removed tumor will have additional testing that will look at different factors that may tell us how aggressive the tumor is and how much FAS is within the tumor. FAS seems to be produced in higher amounts by prostate cancer cells than normal cells. We will then try to determine if the results of the C11 acetate PET scan can tell us how much FAS is produced by prostate cancer cells.
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Prostate Cancer
Procedure: C-11 acetate PET scan
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
May 2006
Not Provided

Inclusion Criteria:

  • Histologically documented prostate cancer
  • Planned radical prostatectomy
  • > 50% cores positive for prostate cancer from prostate biopsy or a palpable prostate nodule
  • Older than 18 years of age

Exclusion Criteria:

  • Inability to lay on a scanner for 60 minutes
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00139191
05-136
Not Provided
Not Provided
Dana-Farber Cancer Institute
  • Beth Israel Deaconess Medical Center
  • Massachusetts General Hospital
Principal Investigator: Robert Ross, MD Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP